D E Duggan

4.3k total citations
76 papers, 3.6k citations indexed

About

D E Duggan is a scholar working on Pharmacology, Molecular Biology and Oncology. According to data from OpenAlex, D E Duggan has authored 76 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Pharmacology, 27 papers in Molecular Biology and 22 papers in Oncology. Recurrent topics in D E Duggan's work include Pharmacogenetics and Drug Metabolism (26 papers), Drug Transport and Resistance Mechanisms (19 papers) and Inflammatory mediators and NSAID effects (12 papers). D E Duggan is often cited by papers focused on Pharmacogenetics and Drug Metabolism (26 papers), Drug Transport and Resistance Mechanisms (19 papers) and Inflammatory mediators and NSAID effects (12 papers). D E Duggan collaborates with scholars based in United States, France and Japan. D E Duggan's co-authors include K.C. Kwan, R.M. Noll, Sidney Udenfriend, S. Vickers, K F Hooke, Jiunn H. Lin, F. Gilbert McMahon, C A Duncan, David M. Cocchetto and Bernard B. Brodie and has published in prestigious journals such as Nature, Journal of the American Chemical Society and Journal of Biological Chemistry.

In The Last Decade

D E Duggan

75 papers receiving 3.3k citations

Peers

Replace Terry V. Zenser with:

Terry V. Zenser United States

Michinao Mizugaki Japan

David Zakim United States

Gerard J. Mulder Netherlands

Heike Gutmann Switzerland

Jordan L. Holtzman United States

J. Noordhoek Netherlands

Gopal Krishna United States

L. F. Chasseaud United States

Urs A. Boelsterli Switzerland

Terry V. Zenser United States View profile →

Citations per field, relative to D E Duggan

D E Duggan · 1×

×1.2 1.4k

MB

×0.8 704

PHARM

×0.6 418

ONCOL

×1.2 828

PHARM

×0.6 272

SURGE

Citations per year, relative to D E Duggan

D E Duggan · 1×

2016

2017

2018

2019

2020

2021

2022

2023

2024

2025

Countries citing papers authored by D E Duggan

Since Specialization

Citations

This map shows the geographic impact of D E Duggan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D E Duggan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D E Duggan more than expected).

Fields of papers citing papers by D E Duggan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D E Duggan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D E Duggan. The network helps show where D E Duggan may publish in the future.

Co-authorship network of co-authors of D E Duggan

This figure shows the co-authorship network connecting the top 25 collaborators of D E Duggan. A scholar is included among the top collaborators of D E Duggan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with D E Duggan. D E Duggan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Biotransformation of lovastatin. V. Species differences in in vivo metabolite profiles of mouse, rat, dog, and human. 1993 ·Drug Metabolism and Disposition ·Rita A. Halpin, E H Ulm, A. E. Till, P H Kari, Kamlesh P. Vyas, D B Hunninghake, D E Duggan	47
2	Effects of dose, sex, and age on the disposition of alendronate, a potent antiosteolytic bisphosphonate, in rats. 1992 ·Drug Metabolism and Disposition ·Jiunn H. Lin, (unknown), D E Duggan	87
3	Physiological Disposition of Hmg-Coa-Reductase Inhibitors 1990 ·Drug Metabolism Reviews ·D E Duggan, S. Vickers	62
4	Dose-dependent pharmacokinetics of MK-417, a potent carbonic anhydrase inhibitor, in rabbits following single and multiple doses. 1990 ·Drug Metabolism and Disposition ·Jiunn H. Lin, (unknown), E H Ulm, (unknown), D E Duggan	4
5	In vitro and in vivo biotransformation of simvastatin, an inhibitor of HMG CoA reductase. 1990 ·Drug Metabolism and Disposition ·S. Vickers, C A Duncan, Kamlesh P. Vyas, P H Kari, Byron H. Arison, Shimoga R. Prakash, Harri G. Ramjit, Steven M. Pitzenberger, G. E. STOKKER, D E Duggan	136
6	High-performance liquid chromatographic determination of cilastatin and its major metabolite N-acetylcilastatin in rat plasma, urine and bile 1990 ·Journal of Chromatography B Biomedical Sciences and Applications ·(unknown), John Y.‐K. Hsieh, Jiunn H. Lin, D E Duggan	1
7	Metabolism of simvastatin s by rat and mouse liver microsomes 1988 ·The FASEB Journal ·Kamlesh P. Vyas, P H Kari, S. Vickers, C. Duncan, Steven M. Pitzenberger, (unknown), Harri G. Ramjit, D E Duggan	1
8	Differential effects of phenobarbital on ester and ether glucuronidation of diflunisal in rats. 1987 ·Journal of Pharmacology and Experimental Therapeutics ·J H Lin, (unknown), E H Ulm, D E Duggan	11
9	Possible mechanisms for reduced plasma clearance of diflunisal in rat experimental renal failure. 1986 ·Journal of Pharmacology and Experimental Therapeutics ·J H Lin, E H Ulm, D E Duggan	13
10	Effect of uremia and anephric state on the pharmacokinetics of sulindac and its metabolites in rats. I. An application of pharmacokinetic model for reversible metabolism. 1985 ·Drug Metabolism and Disposition ·(unknown), K. C. Yeh, D E Duggan	6
11	Effect of uremia and anephric state on the pharmacokinetics of sulindac and its metabolites in rats. II. Differential effects on the biliary excretion. 1985 ·Drug Metabolism and Disposition ·(unknown), K. C. Yeh, D E Duggan	3
12	Kinetics of the tissue distributions of sulindac and metabolites. Relevance to sites and rates of bioactivation. 1980 ·Drug Metabolism and Disposition ·D E Duggan, K F Hooke, Stephen S. Hwang	63
13	Identification of the biologically active form of sulindac. 1977 ·Journal of Pharmacology and Experimental Therapeutics ·D E Duggan, K F Hooke, Edwin A. Risley, (unknown), C. G. Van Arman	115
14	Radioimmunoassay of Indomethacin in Biological Fluids 1977 ·Journal of Pharmaceutical Sciences ·(unknown), (unknown), D E Duggan	20
15	N-GLUCOSIDE FORMATION AS A DETOXIFICATION MECHANISM IN MAMMALS 1974 ·Journal of Pharmacology and Experimental Therapeutics ·D E Duggan, J. J. Baldwin, Byron H. Arison, Ryan E. Rhodes	30
16	Purine Metabolism in the Chick Embryo; Effects of Uricogenesis and Xanthine Oxidase Inhibition 1968 ·Molecular Pharmacology ·D E Duggan, (unknown), (unknown)	4
17	THE ACCUMULATION OF CHLOROTHIAZIDE AND RELATED SALURETIC AGENTS BY ISOLATED RENAL TUBULES 1966 ·Journal of Pharmacology and Experimental Therapeutics ·D E Duggan	9
18	On the metabolic effects of 6-chloropurine. 1961 ·PubMed ·D E Duggan, (unknown), (unknown)	7
19	THE METABOLISM OF 6-CHLOROPURINE-8-C14 IN THE RAT 1960 ·Journal of Pharmacology and Experimental Therapeutics ·D E Duggan, Elwood Titus	11
20	A spectrophotofluorometric study of compounds of biological interest 1957 ·Archives of Biochemistry and Biophysics ·D E Duggan, Robert L. Bowman, Bernard B. Brodie, Sidney Udenfriend	163

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact